Drivers determining tuberculosis disease screening yield in four European screening programmes: a comparative analysis.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
10 2023
Historique:
received: 12 12 2022
accepted: 03 05 2023
medline: 6 11 2023
pubmed: 26 5 2023
entrez: 25 5 2023
Statut: epublish

Résumé

The World Health Organization End TB Strategy emphasises screening for early diagnosis of tuberculosis (TB) in high-risk groups, including migrants. We analysed key drivers of TB yield differences in four large migrant TB screening programmes to inform TB control planning and feasibility of a European approach. We pooled individual TB screening episode data from Italy, the Netherlands, Sweden and the UK, and analysed predictors and interactions for TB case yield using multivariable logistic regression models. Between 2005 and 2018 in 2 302 260 screening episodes among 2 107 016 migrants to four countries, the programmes identified 1658 TB cases (yield 72.0 (95% CI 68.6-75.6) per 100 000). In logistic regression analysis, we found associations between TB screening yield and age (≥55 years: OR 2.91 (95% CI 2.24-3.78)), being an asylum seeker (OR 3.19 (95% CI 1.03-9.83)) or on a settlement visa (OR 1.78 (95% CI 1.57-2.01)), close TB contact (OR 12.25 (95% CI 11.73-12.79)) and higher TB incidence in the country of origin. We demonstrated interactions between migrant typology and age, as well as country of origin. For asylum seekers, the elevated TB risk remained similar above country of origin incidence thresholds of 100 per 100 000. Key determinants of TB yield included close contact, increasing age, incidence in country of origin and specific migrant groups, including asylum seekers and refugees. For most migrants such as UK students and workers, TB yield significantly increased with levels of incidence in the country of origin. The high, country of origin-independent TB risk in asylum seekers above a 100 per 100 000 threshold could reflect higher transmission and re-activation risk of migration routes, with implications for selecting populations for TB screening.

Sections du résumé

BACKGROUND
The World Health Organization End TB Strategy emphasises screening for early diagnosis of tuberculosis (TB) in high-risk groups, including migrants. We analysed key drivers of TB yield differences in four large migrant TB screening programmes to inform TB control planning and feasibility of a European approach.
METHODS
We pooled individual TB screening episode data from Italy, the Netherlands, Sweden and the UK, and analysed predictors and interactions for TB case yield using multivariable logistic regression models.
RESULTS
Between 2005 and 2018 in 2 302 260 screening episodes among 2 107 016 migrants to four countries, the programmes identified 1658 TB cases (yield 72.0 (95% CI 68.6-75.6) per 100 000). In logistic regression analysis, we found associations between TB screening yield and age (≥55 years: OR 2.91 (95% CI 2.24-3.78)), being an asylum seeker (OR 3.19 (95% CI 1.03-9.83)) or on a settlement visa (OR 1.78 (95% CI 1.57-2.01)), close TB contact (OR 12.25 (95% CI 11.73-12.79)) and higher TB incidence in the country of origin. We demonstrated interactions between migrant typology and age, as well as country of origin. For asylum seekers, the elevated TB risk remained similar above country of origin incidence thresholds of 100 per 100 000.
CONCLUSIONS
Key determinants of TB yield included close contact, increasing age, incidence in country of origin and specific migrant groups, including asylum seekers and refugees. For most migrants such as UK students and workers, TB yield significantly increased with levels of incidence in the country of origin. The high, country of origin-independent TB risk in asylum seekers above a 100 per 100 000 threshold could reflect higher transmission and re-activation risk of migration routes, with implications for selecting populations for TB screening.

Identifiants

pubmed: 37230498
pii: 13993003.02396-2022
doi: 10.1183/13993003.02396-2022
pmc: PMC10568038
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: D. Zenner reports grants from Barts Charity, La Caixa Foundation and the European Commission, outside the submitted work. D. Menezes reports grants through project E-DETECT, Work Package 6. V. Marchese reports grant support and travel compensation from E-DETECT TB. The other authors have no potential conflicts of interest to disclose.

Références

Lancet Infect Dis. 2016 Aug;16(8):962-70
pubmed: 27013215
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1075-1085
pubmed: 28911349
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34764184
BMC Infect Dis. 2021 Sep 30;21(1):1023
pubmed: 34592946
J Travel Med. 2021 Jun 1;28(4):
pubmed: 33822988
BMC Infect Dis. 2011 Jan 04;11:3
pubmed: 21205318
Eur Respir J. 2015 Apr;45(4):928-52
pubmed: 25792630
Health Syst Reform. 2022 Jan 1;8(1):e2019571
pubmed: 35060827
Nat Med. 2020 Dec;26(12):1941-1949
pubmed: 33077958
Eur Respir J. 2023 Jun 15;61(6):
pubmed: 37080572
Int J Tuberc Lung Dis. 2022 Jun 1;26(6):500-508
pubmed: 35650693
Respirology. 2010 Jul;15(5):747-63
pubmed: 20546192
N Engl J Med. 2022 Apr 21;386(16):1490-1493
pubmed: 34986295
Eur Respir J. 2021 Mar 18;57(3):
pubmed: 32855227
Lancet. 2016 Nov 19;388(10059):2510-2518
pubmed: 27742165
Lancet Infect Dis. 2018 Oct;18(10):1077-1087
pubmed: 30174209
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637
pubmed: 28482956
Eur Respir J. 2016 Jun;47(6):1870-2
pubmed: 26965289
Int J Infect Dis. 2019 Mar;80S:S45-S49
pubmed: 30826482
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142649
Int J Tuberc Lung Dis. 2022 Oct 1;26(10):942-948
pubmed: 36163670
Travel Med Infect Dis. 2019 Jan - Feb;27:39-45
pubmed: 30347248
Eur Respir J. 2017 Oct 12;50(4):
pubmed: 29025892
Int J Tuberc Lung Dis. 2021 Nov 1;25(11):903-910
pubmed: 34686232
Int J Tuberc Lung Dis. 2005 Nov;9(11):1183-203
pubmed: 16333924
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):965-976
pubmed: 28826445
Lancet Infect Dis. 2014 Dec;14(12):1240-9
pubmed: 25455991
Eur Respir Rev. 2018 Jun 13;27(148):
pubmed: 29898905
Int J Tuberc Lung Dis. 2017 Aug 1;21(8):840-851
pubmed: 28786791
Eur Respir J. 2016 Oct;48(4):1253-1254
pubmed: 27694419
Eur Respir J. 2021 Nov 11;58(5):
pubmed: 34446465
Confl Health. 2020 May 01;14:21
pubmed: 32377233

Auteurs

Dominik Zenner (D)

Faculty of Population Health Sciences, University College London, London, UK d.zenner@qmul.ac.uk.
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Amsterdam University Medical Centers, location University of Amsterdam, Department of Global Health, Amsterdam, The Netherlands.
Amsterdam Public Health, Global Health, Amsterdam, The Netherlands.

Daniella Brals (D)

Amsterdam University Medical Centers, location University of Amsterdam, Department of Global Health, Amsterdam, The Netherlands.
Amsterdam Public Health, Global Health, Amsterdam, The Netherlands.

Joanna Nederby-Öhd (J)

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Dee Menezes (D)

Institute of Health Informatics Research, University College London, London, UK.

Robert Aldridge (R)

Institute of Health Informatics Research, University College London, London, UK.

Sarah R Anderson (SR)

UK Health Security Agency, London, UK.

Gerard de Vries (G)

National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Connie Erkens (C)

KNCV Tuberculosis Foundation, The Hague, The Netherlands.

Valentina Marchese (V)

WHO Collaborating Center for TB/HIV and the TB Elimination Strategy, University of Brescia, Brescia, Italy.

Alberto Matteelli (A)

WHO Collaborating Center for TB/HIV and the TB Elimination Strategy, University of Brescia, Brescia, Italy.

Morris Muzyamba (M)

UK Health Security Agency, London, UK.

Job van Rest (J)

KNCV Tuberculosis Foundation, The Hague, The Netherlands.

Ineke Spruijt (I)

KNCV Tuberculosis Foundation, The Hague, The Netherlands.

John Were (J)

Faculty of Population Health Sciences, University College London, London, UK.

Giovanni Battista Migliori (GB)

Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.

Knut Lönnroth (K)

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Frank Cobelens (F)

Amsterdam University Medical Centers, location University of Amsterdam, Department of Global Health, Amsterdam, The Netherlands.
Amsterdam Public Health, Global Health, Amsterdam, The Netherlands.

Ibrahim Abubakar (I)

Faculty of Population Health Sciences, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH